SpyGlass Pharma (SGP) Stock Analysis

What SpyGlass Pharma does

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Key metrics

ETFs linked to SGP

Broad-market and Healthcare sector ETFs an investor holding SpyGlass Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SGP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for SpyGlass Pharma?

SpyGlass Pharma trades under the ticker SGP on NASDAQ.

Which exchange is SGP listed on?

SGP is listed on NASDAQ.

What sector does SpyGlass Pharma operate in?

SpyGlass Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SGP in a portfolio?

PortView shows SGP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.